[go: up one dir, main page]

WO2008140595A3 - Synthetic trivalent haptens, complexes thereof, and uses therefor - Google Patents

Synthetic trivalent haptens, complexes thereof, and uses therefor Download PDF

Info

Publication number
WO2008140595A3
WO2008140595A3 PCT/US2007/086163 US2007086163W WO2008140595A3 WO 2008140595 A3 WO2008140595 A3 WO 2008140595A3 US 2007086163 W US2007086163 W US 2007086163W WO 2008140595 A3 WO2008140595 A3 WO 2008140595A3
Authority
WO
WIPO (PCT)
Prior art keywords
complexes
molecules
trivalent
haptens
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/086163
Other languages
French (fr)
Other versions
WO2008140595A2 (en
Inventor
Zihni Basar Bilgicer
Demetri T Moustakas
George M Whitesides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of WO2008140595A2 publication Critical patent/WO2008140595A2/en
Publication of WO2008140595A3 publication Critical patent/WO2008140595A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention provides trivalent hapten molecules (trihapten molecules) and complexes thereof. The trivalent hapten molecules are useful for forming relatively stable complexes comprising hapten molecules and divalent ligands (e.g., antibodies) for the hapten molecules. Such trihapten molecules are useful for assays, e.g., of antibodies, or for depleting a ligand from a sample, e.g., for treating a disease by binding an undesirable receptor such as an antibody. Complexes of trivalent hapten molecules are useful for selectively targeting relatively high density, multivalent presentations of haptens, such as occur on cells overexpressing a molecule on their surfaces, such as cancer cells.
PCT/US2007/086163 2006-12-01 2007-11-30 Synthetic trivalent haptens, complexes thereof, and uses therefor Ceased WO2008140595A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87237406P 2006-12-01 2006-12-01
US60/872,374 2006-12-01

Publications (2)

Publication Number Publication Date
WO2008140595A2 WO2008140595A2 (en) 2008-11-20
WO2008140595A3 true WO2008140595A3 (en) 2009-05-14

Family

ID=40002813

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/086163 Ceased WO2008140595A2 (en) 2006-12-01 2007-11-30 Synthetic trivalent haptens, complexes thereof, and uses therefor

Country Status (1)

Country Link
WO (1) WO2008140595A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124743B2 (en) 2006-06-01 2012-02-28 President And Fellows Of Harvard College Purification of a bivalently active antibody using a non-chromatographic method
US20160175458A1 (en) 2014-12-19 2016-06-23 Alkermes, Inc. Single chain fc fusion proteins
JP7084881B2 (en) 2016-06-22 2022-06-15 アルカームス インコーポレーテッド Compositions and Methods for Modulating the Immunostimulatory and Anti-Inflammatory Properties of IL-10
MA57908B1 (en) 2019-11-25 2025-09-30 Alkermes, Inc. SUBSTITUTED MACROCYCLIC COMPOUNDS AND METHODS OF PROCESSING THEM
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4120954A (en) * 1977-04-04 1978-10-17 American Cyanamid Company 2,2',2"-[S-Phenenyltris(carbonylimino) ]tris-2-deoxy-D-glucopyranose and salts thereof
WO1997019106A2 (en) * 1995-11-17 1997-05-29 The Regents Of The University Of California Collagen-like peptoid residue-containing structures
WO2003074148A1 (en) * 2002-02-28 2003-09-12 Rensselaer Polytechnic Institute High-affinity, low-molecular-mass displacers for ion-exchange chromatography
WO2003097587A2 (en) * 2002-05-22 2003-11-27 Applied Nanosystems B.V. Gelling agents
WO2005073240A2 (en) * 2004-01-29 2005-08-11 Vysoká skola chemicko-technologická v Praze Novel hiv protease inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4120954A (en) * 1977-04-04 1978-10-17 American Cyanamid Company 2,2',2"-[S-Phenenyltris(carbonylimino) ]tris-2-deoxy-D-glucopyranose and salts thereof
WO1997019106A2 (en) * 1995-11-17 1997-05-29 The Regents Of The University Of California Collagen-like peptoid residue-containing structures
WO2003074148A1 (en) * 2002-02-28 2003-09-12 Rensselaer Polytechnic Institute High-affinity, low-molecular-mass displacers for ion-exchange chromatography
WO2003097587A2 (en) * 2002-05-22 2003-11-27 Applied Nanosystems B.V. Gelling agents
WO2005073240A2 (en) * 2004-01-29 2005-08-11 Vysoká skola chemicko-technologická v Praze Novel hiv protease inhibitors

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BILGIÇER BASAR ET AL: "A synthetic trivalent hapten that aggregates anti-2,4-DNP IgG into bicyclic trimers.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 129, no. 12, March 2007 (2007-03-01), pages 3722 - 3728, XP002509074 *
CORBELL J B ET AL: "A comparison of biological and calorimetric analyses of multivalent glycodendrimer ligands for concanavalin A", TETRAHEDRON ASYMMETRY, vol. 11, no. 1, 2000, pages 95 - 111, XP004202373 *
FUJII H ET AL: "ANTIMETASTATIC ACTVITIES OF SYNTHETIC ARG-GLY-ASP-SER (RGDS) AND ARG-LEU-ASP-SER (RLDS) PEPTIDE ANALOGUES AND THEIR INHIBITORY MECHANISMS", BIOLOGICAL & PHARMACEUTICAL BULLETIN, vol. 18, no. 12, 1995, pages 1681 - 1688, XP001108987 *
JAYARAMAN N ET AL: "Synthesis of Carbohydrate-Containing Dendrimers. 5. Preparation of Dendrimers Using Unprotected Carbohydrates", TETRAHEDRON LETTERS, vol. 38, no. 38, 1997, pages 6767 - 6770, XP004091785 *
LEUNG D K ET AL: "Synthesis and binding properties of cyclodextrin trimers", TETRAHEDRON LETTERS, vol. 42, no. 36, 2001, pages 6255 - 6258, XP004302922 *
LOU X ET AL: "Radical cation formation in characterization of novel C3-symmetric disks and their precursors by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.", JOURNAL OF MASS SPECTROMETRY, vol. 41, no. 5, May 2006 (2006-05-01), pages 659 - 669, XP002509072 *
MÜLLER P ET AL: "Tethering of long-chain amino acids to a rigid aromatic core - A new type of preorganized surfactants acting as flotative agents", JJOURNAL OF SURFACTANTS AND DETERGENTS, vol. 4, no. 4, 2001, pages 407 - 414, XP002509073 *
MULLER P U ET AL: "Novel amphiphiles with preorganized functionalities-formation of Langmuir-films and efficiency in mineral flotation", ADVANCES IN COLLOID AND INTERFACE SCIENCE, vol. 114-115, 2005, pages 291 - 302, XP004925993 *
PEDRO A AND LEHMANN F: "Conformations of highly hindered aryl ethers - XVIII", TETRAHEDRON, vol. 30, 1974, pages 719 - 726, XP002509069 *
RAO J ET AL: "A trivalent system from vancomycin-D-Ala-D-Ala with higher affinity than avidin-biotin", SCIENCE, vol. 280, no. 5364, 1998, pages 708 - 711, XP002960537 *
RAO J ET AL: "Design, synthesis, and characterization of a high-affinity trivalent system derived from vancomycin and L-Lys-D-Ala-D-Ala", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 122, no. 12, 2000, pages 2698 - 2710, XP002509070 *
SUN SHUGUANG ET AL: "Thermodynamic studies on the recognition of flexible peptides by transition-metal complexes.", INORGANIC CHEMISTRY, vol. 41, no. 6, 2002, pages 1584 - 1590, XP002509071 *

Also Published As

Publication number Publication date
WO2008140595A2 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
WO2008048970A3 (en) Synthetic antibodies
MX358410B (en) Human antibodies to human delta like ligand 4.
WO2007106744A8 (en) Anti-5t4 antibodies and uses thereof
WO2005086875A3 (en) A humanized anti-cea t84.66 antibody and uses thereof
WO2008067547A3 (en) Improved immunoglobulin libraries
WO2007027713A3 (en) Trail receptor 2 polypeptides and antibodies
WO2011094593A3 (en) Novel lowered affinity antibodies and methods of marking the same
WO2006031653A3 (en) Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates
WO2005023986A3 (en) Microrna as ligands and target molecules
EP2348052A3 (en) Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
AU2008257801A8 (en) RSV-specific binding molecules and means for producing them
WO2007129895A3 (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
WO2009140039A3 (en) Synthetic antibodies
WO2008098917A3 (en) Novel antibodies against igf-ir
NO20082524L (en) Biological material and use of the same
WO2008055080A3 (en) Method for blocking non-specific protein binding on a functionalized surface
WO2008140595A3 (en) Synthetic trivalent haptens, complexes thereof, and uses therefor
WO2010088522A3 (en) Novel lowered affinity antibodies and uses therefor
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2007120766A3 (en) Erythropoietin receptor agonists
WO2011064257A3 (en) Monospecific polypeptide reagents
WO2006002895A3 (en) Conjugates of antibody and duoarmycin derivatives as antitumor agents
WO2006034278A3 (en) Methods and compositions for detecting cancer using components of the u2 spliceosomal particle
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
WO2008081331A3 (en) Enhancing the level of antibody expression by framework re-engineering

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07874329

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07874329

Country of ref document: EP

Kind code of ref document: A2